Temporary blockade of interferon-? ameliorates doxorubicin-induced cardiotoxicity without influencing the anti-tumor effect - 27/10/20
páginas | 8 |
Iconografías | 6 |
Vídeos | 0 |
Otros | 0 |
Graphical abstract |
Highlights |
• | Simultaneous IFN-γ blockade ameliorates DOX-induced chronic cardiotoxicity. |
• | Late IFN-γ blockade alleviates DOX-induced heart dysfunction in tumor-bearing mice. |
• | Late IFN-γ blockade does not affect DOX’s anti-tumor effect. |
Abstract |
Doxorubicin (DOX) is commonly used as an anti-cancer agent. However, its severe cardiotoxicity often makes it life threatening even long after DOX therapy during childhood. We recently reported interferon-γ (IFN-γ) necessary for DOX-induced acute cardiotoxicity in a p38 dependent way and, asked here for the potential of IFN-γ blockade to prevent DOX-induced chronic cardiotoxicity during tumor therapy. In our model system, mice without or with growing tumors repeatedly received DOX treatment. Simultaneous injection of anti-IFN-γ antibody R46-A2 with DOX to block IFN-γ signal efficiently protected the cardiac function of DOX treated recipients. Importantly, a single late injection of R46-A2 after DOX exposure also ameliorated DOX induced cardiac dysfunction in tumor-bearing mice. The anti-IFN-γ treatment did not affect the DOX-mediated tumor suppression effect and it left the main cellular immune response intact. Therefore, temporary blockade of IFN-γ may represent a novel strategy to ameliorate established DOX induced cardiotoxicity (DIC) or prevent its development in tumor therapy.
El texto completo de este artículo está disponible en PDF.Keywords : IFN-γ, Doxorubicin, Cardiotoxicity, Tumor therapy
Esquema
Vol 130
Artículo 110587- octobre 2020 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
La compra de artículos no está disponible en este momento.
¿Ya suscrito a @@106933@@ revista ?